分類彙整：公司新聞

Administration of a single broadly neutralizing human immunodeficiency virus (HIV)–specific antibody to HIV-infected persons leads to the development of antibody-resistant virus in the absence of antiretroviral therapy (ART). It is possible that monotherapy with UB-421, an antibody that blocks the virus-binding site on human CD4+ T cells, could induce sustained virologic suppression without induction of resistance in HIV-infected persons after analytic treatment interruption. 繼續閱讀 →

HIV treatment has come a long way since the early days of the epidemic. Patients can now take various combinations of dozens of medications keep the virus under control and halt their disease from decimating their immune systems and leading to more serious, often fatal outcomes.

But harnessing HIV requires daily vigilance. Missing doses of the pills can give the virus the chance to develop resistance to the drugs and lead to a surge in new copies of HIV that flood the body.

In a new study published in the New England Journal of Medicine, researchers at Taiwan-based United BioPharma report encouraging results with a single injection that seems to stymie HIV as well as daily pill regimens. The results add to a growing number of studies suggesting that patients may be able to take pill holidays without putting their health at risk. 繼續閱讀 →

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV. The study was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and United Biopharma, Inc. 繼續閱讀 →

United BioPharma Announces Publication of Breakthrough HIV Clinical

Trial Data in the New England Journal of Medicine 繼續閱讀 →

聯合生物製藥(股)公司(聯生藥)今日宣布,其治療 HIV 感染之抗體新藥 UB-421
之臨床 II 期試驗結果以「Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound
after Treatment Interruption」為題的原創論文,榮獲刊登於最新一期的新英格
蘭醫學期刊(The New England Journal of Medicine, NEJM)。 繼續閱讀 →

UB-421 Q & A 繼續閱讀 →

For two decades, biotech companies trying to tackle Alzheimer’s disease have had little success. While vaccines have often shown promise for certain patients, they’ve come with devastating side effects for others—brain swelling, for example—because researchers haven’t been able to reliably keep patients’ immune systems from kicking into overdrive when exposed to the vaccines. Now, a four-year old Dublin startup believes it may be on to something. 繼續閱讀 →

2018 維也納聖誕音樂會 繼續閱讀 →

愛因斯坦曾富哲理地說過：「有時候『重要的』無法計算，能計算的又不重要。」知識，正具有無法量化的重要性。 繼續閱讀 →

Watch This CEO Discuss A Potentially Ground-Breaking Vaccine for Alzheimers 繼續閱讀 →

Mei Mei Hu | Democratizing Brain Health | Global Summit 2018 | Singularity University 繼續閱讀 →

Tune in to watch sessions with a star-studded group of women, including Alphabet CFO Ruth Porat, U.S. Secretary of Transportation Elaine Chao, New York Stock Exchange president Stacey Cunningham, United Neuroscience CEO Mei Mei Hu, Land O’ Lakes CEO CEO Beth Ford, Estonia president Kersti Kaljulaid, NBC News host Megyn Kelly, Walmart International CEO Judith McKenna, and Bumble CEO Whitney Wolfe Herd. 繼續閱讀 →

聯亞集團與長庚大學建教合作-107學年度暑期實習成果競賽於107年9月3日圓滿順利完成，實習生們皆有非常優異的傑出表現！ 繼續閱讀 →

聯生藥預計8/29停止興櫃買賣，轉往海外掛牌！董事王長怡表示，根留台灣信念不變，將持續投資台灣，未來五年至少再投入數十億用於人才培育、新藥研發，且將再擴建至12條2,000公升生產線。 繼續閱讀 →

聯合生物製藥為長期發展策略，董事會決議終止櫃檯買賣(新聞稿&問答集) 繼續閱讀 →